Clinical Trial Update: CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing CT-2103/Carboplatin vs Paclitaxel/Carboplatin for non-small cell lung cancer in women with estradiol > 25 pg/mL was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CT-2103/Carboplatin (CT-2103, carboplatin)
• Paclitaxel/Carboplatin (paclitaxel, carboplatin)

Snippet

Sponsor: CTI BioPharma | Conditions: NSCLC | Phase 3 | Status: WITHDRAWN